| Overview |
| bsm-54199R |
| Growth hormone receptor (3C5) Monoclonal Antibody |
| WB, FCM, IHC-P, IF(IHC-P), IF(ICC) |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| Synthetic peptide within human Growth hormone receptor aa 500-630 |
| Monoclonal |
| 3C5 |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 1xTBS (pH7.4), 1%BSA, 40%Glycerol and 0.05% Sodium Azide. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 2690 |
| P10912 |
| Growth hormone receptor; Somatotropin receptor; Growth hormone-binding protein; Serum-binding protein; GH receptor; GH-binding protein; GHBP; GHR. |
| GHR is a member of the type I cytokine receptor family, which is a transmembrane receptor for growth hormone. It is a receptor for pituitary gland growth hormone involved in regulating postnatal body growth. Binding of growth hormone to the receptor leads to receptor dimerization and the activation of an intra- and intercellular signal transduction pathway leading to growth. On ligand binding, couples to the JAK2/STAT5 pathway. The soluble form (GHBP) acts as a reservoir of growth hormone in plasma and may be a modulator/inhibitor of GH signaling. Isoform 2 up-regulates the production of GHBP and acts as a negative inhibitor of GH signaling. Mutations in this gene have been associated with Laron syndrome, also known as the growth hormone insensitivity syndrome (GHIS), a disorder characterized by short stature. In humans and rabbits, but not rodents, growth hormone binding protein (GHBP) is generated by proteolytic cleavage of the extracellular ligand-binding domain from the mature growth hormone receptor protein. Multiple alternatively spliced transcript variants have been found for this gene |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IHC-P |
1:200-400 |
| IF(IHC-P) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz